BR112022013042A2 - Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade - Google Patents
Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidadeInfo
- Publication number
- BR112022013042A2 BR112022013042A2 BR112022013042A BR112022013042A BR112022013042A2 BR 112022013042 A2 BR112022013042 A2 BR 112022013042A2 BR 112022013042 A BR112022013042 A BR 112022013042A BR 112022013042 A BR112022013042 A BR 112022013042A BR 112022013042 A2 BR112022013042 A2 BR 112022013042A2
- Authority
- BR
- Brazil
- Prior art keywords
- obesity
- diabetes
- treat
- compound
- formula
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 201000001421 hyperglycemia Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 abstract 1
- 108010019598 Liraglutide Proteins 0.000 abstract 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002701 liraglutide Drugs 0.000 abstract 1
- 229950011186 semaglutide Drugs 0.000 abstract 1
- 108010060325 semaglutide Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pens And Brushes (AREA)
- Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911397405 | 2019-12-30 | ||
| CN202011053306 | 2020-09-29 | ||
| PCT/CN2020/141057 WO2021136303A1 (zh) | 2019-12-30 | 2020-12-29 | 长效glp-1化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013042A2 true BR112022013042A2 (pt) | 2022-10-18 |
Family
ID=76687327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013042A BR112022013042A2 (pt) | 2019-12-30 | 2020-12-29 | Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240239859A1 (https=) |
| EP (1) | EP4086277A4 (https=) |
| JP (1) | JP2023510218A (https=) |
| KR (1) | KR20220119731A (https=) |
| CN (5) | CN119060162A (https=) |
| AU (1) | AU2020418207A1 (https=) |
| BR (1) | BR112022013042A2 (https=) |
| CA (1) | CA3166496A1 (https=) |
| MX (1) | MX2022008139A (https=) |
| WO (1) | WO2021136303A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118754967A (zh) * | 2019-12-30 | 2024-10-11 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| EP4086277A4 (en) * | 2019-12-30 | 2024-02-14 | Gan & Lee Pharmaceuticals Co., Ltd. | Long-acting glp-1 compound |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| CN117561072A (zh) * | 2021-06-25 | 2024-02-13 | 甘李药业股份有限公司 | 含glp-1化合物的药物组合物 |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| US20250115654A1 (en) * | 2021-11-12 | 2025-04-10 | Fujian Shengdi Pharmaceutical Co., Ltd. | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
| US20250340610A1 (en) * | 2022-01-28 | 2025-11-06 | Gan & Lee Pharmaceuticals Co., Ltd. | Acylated insulin |
| WO2024179606A1 (zh) * | 2023-03-02 | 2024-09-06 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| CN121219311A (zh) * | 2023-05-24 | 2025-12-26 | 联邦生物科技(珠海横琴)有限公司 | 一种胰岛素衍生物及其应用 |
| CN121464152A (zh) * | 2023-06-30 | 2026-02-03 | 株式会社汇恩斯拉布 | 以glp类似物为有效成分的用于预防或治疗肥胖的药物组合物 |
| WO2025098415A1 (zh) * | 2023-11-06 | 2025-05-15 | 甘李药业股份有限公司 | 用于降糖的glp-1化合物 |
| WO2025098416A1 (zh) * | 2023-11-06 | 2025-05-15 | 甘李药业股份有限公司 | 用于减肥的glp-1化合物 |
| WO2025098457A1 (zh) * | 2023-11-07 | 2025-05-15 | 甘李药业股份有限公司 | 用于降糖的酰化胰岛素 |
| WO2025098502A1 (zh) * | 2023-11-08 | 2025-05-15 | 甘李药业股份有限公司 | 包含胰岛素衍生物的药物组合物的治疗用途 |
| TW202529797A (zh) * | 2023-12-12 | 2025-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ199391A (en) | 1981-01-02 | 1985-12-13 | Genentech Inc | Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DK336188D0 (da) | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | Propeptider |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| IL93282A (en) | 1989-02-09 | 1995-08-31 | Lilly Co Eli | Insulin analogues |
| EP1132404A3 (en) | 1993-09-17 | 2002-03-27 | Novo Nordisk A/S | Acylated insulin |
| WO1995016708A1 (en) | 1993-12-17 | 1995-06-22 | Novo Nordisk A/S | Proinsulin-like compounds |
| US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| KR0150565B1 (ko) | 1995-02-15 | 1998-08-17 | 김정재 | 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법 |
| EP0741188A3 (en) | 1995-05-05 | 1999-07-14 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| JP2003522099A (ja) | 1998-02-27 | 2003-07-22 | ノボ ノルディスク アクティーゼルスカブ | 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン |
| CA2572770A1 (en) * | 2004-07-08 | 2006-01-19 | Novo-Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| TWI362392B (en) * | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US9150633B2 (en) * | 2007-08-15 | 2015-10-06 | Novo Nordisk A/S | Insulin analogues with an acyl and alkylene glycol moiety |
| JP5721432B2 (ja) * | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100292133A1 (en) * | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| HUE032284T2 (en) * | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| US8788849B2 (en) * | 2011-02-28 | 2014-07-22 | Sandisk Technologies Inc. | Method and apparatus for protecting cached streams |
| EP2866825B1 (en) * | 2012-07-01 | 2020-04-08 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| ES2908373T3 (es) * | 2015-08-25 | 2022-04-28 | Novo Nordisk As | Nuevos derivados de insulina y los usos médicos de los mismos |
| EP3922260A3 (en) * | 2016-05-24 | 2022-06-15 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists and glp-1 analogues |
| PE20210857A1 (es) * | 2016-12-16 | 2021-05-18 | Novo Nordisk As | Composiciones farmaceuticas que contienen insulina |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| WO2019200594A1 (zh) * | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| CN118754967A (zh) * | 2019-12-30 | 2024-10-11 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| EP4086277A4 (en) * | 2019-12-30 | 2024-02-14 | Gan & Lee Pharmaceuticals Co., Ltd. | Long-acting glp-1 compound |
-
2020
- 2020-12-29 EP EP20909624.7A patent/EP4086277A4/en active Pending
- 2020-12-29 JP JP2022540870A patent/JP2023510218A/ja active Pending
- 2020-12-29 CN CN202411172489.0A patent/CN119060162A/zh active Pending
- 2020-12-29 BR BR112022013042A patent/BR112022013042A2/pt unknown
- 2020-12-29 AU AU2020418207A patent/AU2020418207A1/en active Pending
- 2020-12-29 CN CN202411172407.2A patent/CN119060161A/zh active Pending
- 2020-12-29 CN CN202080091240.0A patent/CN114901680B/zh active Active
- 2020-12-29 CN CN202411172451.3A patent/CN119529057A/zh active Pending
- 2020-12-29 US US17/758,113 patent/US20240239859A1/en active Pending
- 2020-12-29 CN CN202411172559.2A patent/CN119060163A/zh active Pending
- 2020-12-29 WO PCT/CN2020/141057 patent/WO2021136303A1/zh not_active Ceased
- 2020-12-29 MX MX2022008139A patent/MX2022008139A/es unknown
- 2020-12-29 CA CA3166496A patent/CA3166496A1/en active Pending
- 2020-12-29 KR KR1020227026310A patent/KR20220119731A/ko active Pending
-
2024
- 2024-09-12 US US18/883,592 patent/US20250011385A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20250011385A1 (en) | 2025-01-09 |
| CN119529057A (zh) | 2025-02-28 |
| CN119060161A (zh) | 2024-12-03 |
| MX2022008139A (es) | 2022-10-03 |
| CA3166496A1 (en) | 2021-07-08 |
| CN119060163A (zh) | 2024-12-03 |
| JP2023510218A (ja) | 2023-03-13 |
| WO2021136303A1 (zh) | 2021-07-08 |
| CN114901680A (zh) | 2022-08-12 |
| KR20220119731A (ko) | 2022-08-30 |
| EP4086277A1 (en) | 2022-11-09 |
| AU2020418207A1 (en) | 2022-08-25 |
| CN114901680B (zh) | 2024-09-27 |
| US20240239859A1 (en) | 2024-07-18 |
| CN119060162A (zh) | 2024-12-03 |
| EP4086277A4 (en) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013042A2 (pt) | Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade | |
| MY187988A (en) | Composition for treating hyperlipidemia comprising oxyntomodulin derivative | |
| MX2023008330A (es) | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. | |
| BR112023003168A2 (pt) | Compostos como agonistas do glp-1r | |
| BR112018067442A8 (pt) | Composto, composição farmacêutica, método de inibir a atividade da amina oxidase, método de tratar uma condição e uso de um composto | |
| CL2018000299A1 (es) | Composiciones con potenciadores de impregnacion para el suministro de fármacos. | |
| NI200700064A (es) | Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos. | |
| BR112018077457A2 (pt) | composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado | |
| MX391293B (es) | DERIVADOs DE OXINTOMODULINA NOVEDOSOS Y COMPOSICION FARMACEUTICA PARA TRATAR LA OBESIDAD QUE COMPRENDE LOS MISMOS. | |
| MX2016015669A (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon. | |
| ECSP10010684A (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad. | |
| BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
| EA201490489A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos | |
| ECSP10010106A (es) | Trans-clomifeno para el síndrome metabólico | |
| MX2022006903A (es) | Productos orales con irritacion reducida. | |
| BR112017013845A2 (pt) | derivados de glucagon | |
| BR112016017897A8 (pt) | uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação | |
| MX392182B (es) | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| ZA202304235B (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| ZA202304233B (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| ZA202304234B (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| MX2025000641A (es) | Composiciones y métodos para el tratamiento del trastorno metabólico y el hígado | |
| BR112022007998A2 (pt) | Novo composto e composição farmacêutica para prevenção ou tratamento de câncer que compreende os mesmos | |
| BR112022004038A2 (pt) | Composições veterinárias granulares palatáveis |